Mergers & Acquisitions

Talaris Therapeutics, Inc. (NasdaqGM: TALS)

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Talaris Therapeutics, Inc. (NasdaqGM: TALS) with Tourmaline Bio, Inc. pursuant to which Talaris shareholders will end up owning approximately 21.3% of the combined company, each on a fully diluted basis. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company.

If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or fill out the form on this page.